File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese

TitleClinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese
Authors
Keywordsβ-Interferon
Expanded disability status scale score
Hong Kong Chinese
Relapsing remitting multiple sclerosis
Secondary progression multiple sclerosis
Issue Date2011
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/clineuro
Citation
Clinical Neurology And Neurosurgery, 2011, v. 113 n. 8, p. 617-622 How to Cite?
AbstractBackground: Clinical outcome of Chinese relapsing remitting multiple sclerosis (RRMS) patients is uncertain. Aim: To study the long-term clinical outcome of Chinese RRMS patients. Method: RRMS patients with duration of 10 years or longer followed up in our hospital is retrospectively studied. Results: 61 RRMS patients (75% female) were studied. Their mean symptom onset age was 25.9 years and mean duration was 20.6 years (range 10-33); 36% patients had received β-interferon and 30% azathioprine. Their mean EDSS scores were 3.3 (range 1-7) and 4.7 (range 1-8) at 10 years and latest follow-up (mean duration 20.6 years) respectively. At 10 years, 30% patients had EDSS score ≤2, 34% EDSS 2.5-3.5, 20% EDSS 4.0-5.5 and 16% ≥6; 18% developed SPMS. At latest follow-up, 15% patients had EDSS ≤2, 20% EDSS 2.5-3.5, 19% EDSS 4.0-5.5 and 46% ≥6.0; 53% developed SPMS. The median time from symptom onset to EDSS 6 was 22 years. No differences were detected in demographic characteristics, presenting neurological features, number of attacks in first 2 years, neuroradiological findings and disease modifying therapies between patients with EDSS <6 and ≥6 at ten years. EDSS scores at 10 years and latest follow-up were similar for patients who had received β-interferon and those who had not. Conclusion: Hong Kong Chinese RRMS patients may have worse long-term clinical outcome than Caucasian patients. © 2011 Elsevier B.V.
Persistent Identifierhttp://hdl.handle.net/10722/133643
ISSN
2015 Impact Factor: 1.198
2015 SCImago Journal Rankings: 0.555
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, KHen_HK
dc.contributor.authorTsang, KLen_HK
dc.contributor.authorHo, PWLen_HK
dc.contributor.authorTse, CTen_HK
dc.contributor.authorKwan, JSCen_HK
dc.contributor.authorHo, JWMen_HK
dc.contributor.authorChu, ACYen_HK
dc.contributor.authorChang, RSKen_HK
dc.contributor.authorHo, SLen_HK
dc.date.accessioned2011-05-24T02:12:50Z-
dc.date.available2011-05-24T02:12:50Z-
dc.date.issued2011en_HK
dc.identifier.citationClinical Neurology And Neurosurgery, 2011, v. 113 n. 8, p. 617-622en_HK
dc.identifier.issn0303-8467en_HK
dc.identifier.urihttp://hdl.handle.net/10722/133643-
dc.description.abstractBackground: Clinical outcome of Chinese relapsing remitting multiple sclerosis (RRMS) patients is uncertain. Aim: To study the long-term clinical outcome of Chinese RRMS patients. Method: RRMS patients with duration of 10 years or longer followed up in our hospital is retrospectively studied. Results: 61 RRMS patients (75% female) were studied. Their mean symptom onset age was 25.9 years and mean duration was 20.6 years (range 10-33); 36% patients had received β-interferon and 30% azathioprine. Their mean EDSS scores were 3.3 (range 1-7) and 4.7 (range 1-8) at 10 years and latest follow-up (mean duration 20.6 years) respectively. At 10 years, 30% patients had EDSS score ≤2, 34% EDSS 2.5-3.5, 20% EDSS 4.0-5.5 and 16% ≥6; 18% developed SPMS. At latest follow-up, 15% patients had EDSS ≤2, 20% EDSS 2.5-3.5, 19% EDSS 4.0-5.5 and 46% ≥6.0; 53% developed SPMS. The median time from symptom onset to EDSS 6 was 22 years. No differences were detected in demographic characteristics, presenting neurological features, number of attacks in first 2 years, neuroradiological findings and disease modifying therapies between patients with EDSS <6 and ≥6 at ten years. EDSS scores at 10 years and latest follow-up were similar for patients who had received β-interferon and those who had not. Conclusion: Hong Kong Chinese RRMS patients may have worse long-term clinical outcome than Caucasian patients. © 2011 Elsevier B.V.en_HK
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/clineuroen_HK
dc.relation.ispartofClinical Neurology and Neurosurgeryen_HK
dc.subjectβ-Interferonen_HK
dc.subjectExpanded disability status scale scoreen_HK
dc.subjectHong Kong Chineseen_HK
dc.subjectRelapsing remitting multiple sclerosisen_HK
dc.subjectSecondary progression multiple sclerosisen_HK
dc.titleClinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chineseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0303-8467&volume=&spage=&epage=&date=2011&atitle=Clinical+outcome+of+relapsing+remitting+multiple+sclerosis+among+Hong+Kong+Chinese-
dc.identifier.emailHo, PWL: hwl2002@hku.hken_HK
dc.identifier.emailChu, ACY: bcccy@hkucc.hku.hken_HK
dc.identifier.emailHo, SL: slho@hku.hken_HK
dc.identifier.authorityHo, PWL=rp00259en_HK
dc.identifier.authorityChu, ACY=rp00505en_HK
dc.identifier.authorityHo, SL=rp00240en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clineuro.2011.04.013en_HK
dc.identifier.pmid21621913en_HK
dc.identifier.scopuseid_2-s2.0-80052183109en_HK
dc.identifier.hkuros185214en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80052183109&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume113en_HK
dc.identifier.issue8en_HK
dc.identifier.spage617en_HK
dc.identifier.epage622en_HK
dc.identifier.isiWOS:000294887900003-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridChan, KH=7406034963en_HK
dc.identifier.scopusauthoridTsang, KL=7201554745en_HK
dc.identifier.scopusauthoridHo, PWL=25027612100en_HK
dc.identifier.scopusauthoridTse, CT=50361920200en_HK
dc.identifier.scopusauthoridKwan, JSC=36479956300en_HK
dc.identifier.scopusauthoridHo, JWM=8685214100en_HK
dc.identifier.scopusauthoridChu, ACY=24343085700en_HK
dc.identifier.scopusauthoridChang, RSK=54793899800en_HK
dc.identifier.scopusauthoridHo, SL=25959633500en_HK
dc.identifier.citeulike9419052-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats